Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40

Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Hospital M&A Dropped in Q4:15

Hospital M&A Dropped in Q4:15

by | Jan 27, 2016 8:30 am | Hospitals

The hospital acquisition market declined in the fourth quarter of 2015, falling 31% from the third quarter’s total of 32 deals. The 22 publicly announced hospital acquisitions in Q4:15 were also 29% lower than the 31 deals announced in the same quarter in 2014. The largest acquisition in the fourth quarter to come with a disclosed price was the acquisition of Al Noor Hospitals Group plc, based in Abu Dhabi, United Arab Emirates, by the South African hospital operator Mediclinic International Ltd. for $2.3 billion. Al Noor Hospitals Group provides primary, secondary and tertiary care services through its hospitals and medical centers in the UAE. Mediclinic International operates... Read More »
Select Medical Acquires Physiotherapy

Select Medical Acquires Physiotherapy

by | Jan 26, 2016 8:00 am | Hospitals, Rehabilitation

Select Medical Holdings Corporation (NYSE: SEM) announced today it has entered into a merger agreement to acquire Physiotherapy Associates Holdings, Inc. for $400 million in cash. Physiotherapy is a national provider of outpatient physical rehabilitation care offering a wide range of services, such as general orthopedics, spinal care and neurological rehabilitation, and orthotics and prosthetics services. As of September 30, 2015, Select operated 110 long term acute care hospitals and 17 acute medical rehabilitation hospitals in 28 states, and 1,033 outpatient rehabilitation clinics in 31 states and the District of Columbia. This acquisition continues their growth. In 2015, Select formed a... Read More »

Q4:15 Health Care M&A Results Are In

by | Jan 22, 2016 8:18 pm | Healthcare Market Updates

It’s hard to see a total of 370 deals in one quarter as a disappointment, but it may be, for some. That’s the current total of health care transactions we have for the last three months of 2015. Compared with the third quarter, however, the fourth quarter deal volume dropped almost 10%. Deal volume in Q3:15 has reached 409 deals, topping the 400-transaction mark for the first time ever. Healthcare services made up a robust 67% of the deal volume in Q4:15, the segment’s strongest showing in the previous four quarters. Thanks to the mega-deals in the Pharmaceutical segment, spending for the fourth quarter was $202.0 billion, up 1% compared with the third quarter’s... Read More »
J&J Slices Its Medical Device Division

J&J Slices Its Medical Device Division

by | Jan 21, 2016 9:12 pm | Medical Devices

Johnson & Johnson (NYSE: JNJ) announced the restructuring of its medical devices business on January 19, 2016. Its 8K filing noted pre-tax restructuring charges of $2.0 billion to $2.4 billion, expected to be incurred this year, as well as a Q4:15 charge of approximately $600 million. About 4% to 6% of the division’s global workforce will get walking papers over the next two years, resulting in a $500 million charge for severance. On a more upbeat note, JNJ expects to see annualized pre-tax cost savings of $800 million to $1.0 billion. This move comes as the market for medical devices has slowed, particularly in the United States. As one of many cost-cutting measures, U.S.... Read More »
Hospital M&A Dropped in Q4:15

Jefferson Expands Again

by | Jan 20, 2016 9:05 pm | Hospitals

Aria Health, a not-for-profit hospital system serving the residents of northeast Philadelphia and lower Bucks County, reached a definitive agreement with Jefferson, the system created last year through the merger of Jefferson Health and Abington Health. That transaction, announced in January 2015 and finalized in May, created an organization with five hospitals, 1,751 inpatient beds, seven outpatient centers and 3,370 physicians. This transaction with Aria adds three hospitals in Frankford, Torresdale and Oxford Valley with 485 licensed beds. Aria also holds an option to develop property on a 41-acre farm in Lower Makefield, Pennsylvania. Under terms of the agreement, Aria will be... Read More »
Managed Care Consolidation in Minnesota

Managed Care Consolidation in Minnesota

by | Jan 19, 2016 8:48 pm | Managed Care

Even as Minnetonka, Minnesota-based UnitedHealth Group (NYSE: UNH) reported larger-than-expected losses in its health-exchange segment in the fourth quarter, a smaller Minnesota managed care company found relief from its own health exchange losses. PreferredOne, based in Golden Valley, was acquired by Fairview Health Services in Minneapolis for an undisclosed price. Fairview is a not-for-profit, integrated health system that has partnered with the University of Minnesota. PreferredOne serves more than 1,500 employers and 285,000 members. The company enjoyed dramatic growth in the first year that the state’s healthcare exchange, MNsure, opened, but it was forced to drop out in 2015... Read More »
Pharma Cozies Up to Diagnostic Labs

Pharma Cozies Up to Diagnostic Labs

by | Jan 15, 2016 9:25 pm | Laboratories, MRI & Dialysis

Last year, the Laboratory, MRI & Dialysis sector posted robust deal volume, relatively speaking. The total of 52 announced transactions was a 58% gain compared with the year before, and better than every year since 2007, when 54 deals were announced (see the chart below). Two of the deals targeting a diagnostic lab or technology were made by major pharmaceutical companies. The common thread we’re seeing as we look back in our database is that these pharma companies are gaining another entry to physician practices, like the camel getting its nose under the tent. The largest deal was OPKO Health’s (NYSE: OPK) $1.47 billion acquisition of Bio-Reference Laboratories (NASDAQ:... Read More »
Nestlé Health Buys into Microbiome Therapy

Nestlé Health Buys into Microbiome Therapy

by | Jan 15, 2016 9:24 pm | Pharmaceuticals

Nestlé Health Science, a subsidiary of Nestlé (NESN.VX), added to its portfolio of nutrition solutions, diagnostics, devices and drugs last week. The company paid $120 million to Seres Therapeutics (NASDAQ: MCRB) to develop and commercialize its product candidates now in development for the treatment of clostridium difficile (c-diff) infection and inflammatory bowel disease (IBD), outside the United States and Canada. The agreement supports the expansion of Seres’ portfolio in markets outside of the United States and Canada and gives financial support for its ongoing R&D. Seres retains full commercial rights to its entire portfolio of product candidates in the United States and... Read More »